Skip Navigation


NDT Advance Access originally published online on April 16, 2007
Nephrology Dialysis Transplantation 2007 22(7):1815-1819; doi:10.1093/ndt/gfm224
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/1815    most recent
gfm224v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mark, P. B.
Right arrow Articles by Jardine, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mark, P. B.
Right arrow Articles by Jardine, A. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Are we overestimating left ventricular abnormalities in end-stage renal disease?

Patrick B. Mark, Rajan K. Patel and Alan G. Jardine

BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK

Correspondence and offprint requests to: Dr Patrick B. Mark, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK. Email: p.mark@clinmed.gla.ac.uk

Keywords: cardiomyopathy; dialysis; echocardiography magnetic resonance imaging; end stage renal failure; left ventricular hypertrophy

The first 150 words of the full text of this article appear below.



   Introduction
 
Uraemic cardiomyopathy, defined by the presence of left ventricular hypertrophy (LVH), left ventricular (LV) dilatation or LV systolic dysfunction (LVSD), is reported to be a predictor of premature cardiovascular mortality in patients with end-stage renal disease (ESRD) [1]. Each of these LV abnormalities cumulatively confers a poorer long term prognosis [2]. LV function, dimensions and geometry have conventionally been assessed by echocardiography. Echocardiography is well established, portable and widely available and therefore will remain a vital clinical tool. However, echocardiography has drawbacks, including operator-dependence and difficulty in obtaining satisfactory acoustic windows. A major technological limitation of echocardiography is the geometric assumption required to calculate LV mass and function. Using conventional M-mode echocardiography to assess LV mass by the Penn [3] or ASE formulae [4], ventricular dimensions are measured in the minor axis and then volumes estimated from the cube of these values, . . . [Full Text of this Article]



   Comparisons between echocardiography and cardiac magnetic resonance imaging for measurement of LV dimensions
 


   Uraemic cardiomyopathy as assessed by cardiac magnetic resonance imaging
 


   Can CMR allow us to improve echocardiographic methods in patients with ESRD?
 


   Improvements to echocardiographic technique for assessment of left ventricular mass
 


   Limitations of CMR
 


   Implications for treatment of uraemic cardiomyopathy
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?